Navigation Links
Generex Common Stock Now Quoted on the Over-the-Counter Bulletin Board
Date:11/4/2010

WORCESTER, Mass., Nov. 4, 2010 /PRNewswire-FirstCall/ -- Generex Biotechnology Corporation (www.generex.com) (OTC Bulletin Board: GNBT) announced today that trades in its common stock are now quoted on the over-the-counter Bulletin Board (OTCBB) under the symbol GNBT.OB.  As Generex is in full compliance with its Securities and Exchange Commission filing obligations, the Company's common stock is eligible for an OTCBB quotation.  The OTCBB is a regulated quotation service that displays real-time quotes, last-sale prices, and volume information in over-the-counter equity securities.

"An OTCBB quotation is a reflection of the importance Generex management attaches to timely and accurate financial reporting and transparency," said Mark Fletcher, the Company's Interim President & Chief Executive Officer.

For more information on the OTCBB, visit www.otcbb.com.

About Generex Biotechnology Corporation

Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies.  Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs).  The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device.  The Company's buccal insulin spray product, Generex Oral-lyn™, which has been approved in India, Lebanon, Algeria, and Ecuador for the treatment of subjects with Type-1 and Type-2 diabetes, is in Phase III clinical trials at several sites around the world.  Antigen Express, Inc. is a wholly owned subsidiary of Generex.  The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases.  For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.

Safe Harbor Statement

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects," or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts.  Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not.  Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement.  No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements.  Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.  Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials.  Because of this, statements regarding the expected timing of clinical trials or ultimate regulatory approval cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials or when it will obtain ultimate regulatory approval by a particular regulatory agency.  Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.


'/>"/>
SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Generex to Participate in Canadian Diabetes Association Conference
2. Generex Reschedules Live Video Webcast
3. Generex Announces Approval of Adjournment Proposal and Adjourned Special Meeting Date
4. Generex Announces That Adjournment Will be Sole Matter Considered at Reconvened Special Meeting of Stockholders on October 15, 2010
5. Generex Provides Clarification for Special Meeting Voting
6. Generex Reaches Agreement to Acquire 51% Stake in Global Medical Direct, a Nationwide Durable Medical Equipment and Pharmaceutical Provider Specializing in Direct-to-Consumer Diabetes Supplies
7. Generex Biotechnology Provides a Corporate Update to Address Managements Strategic Initiatives for Growth
8. Generex Awarded a New Patent in Canada for its Proprietary Buccal Drug Delivery System
9. Generex Presents Abstract at EASD Annual Meeting
10. Generex Announces Sales Agreement with Elias Shaker & Company
11. Generex Announces Approval of Adjournment Proposal and Adjourned Special Meeting Date
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... 2017   Orion Health ™ announced ... medicine platform to the Amazon Web Services, Inc. ... million patient records globally. "We are impressed ... solutions built on modern, scalable technology," said Steve ... "The AWS Cloud gives healthcare companies a powerful tool ...
(Date:2/20/2017)... -- Today from HIMSS17, Ambra Health , makers of ... launch of  Ambra for Developers , a ... RESTful web-services, this is the first cloud development platform ... new APIs, IT departments at health systems and hospitals ... applications such as population health or reporting tools. In ...
(Date:2/20/2017)... Research and Markets has announced the addition of the ... report to their offering. ... An increasing number of patients suffering ... tension free repair procedures and increasing demand for minimally invasive ... market. However, Inconsistent reimbursement and the high cost of hernia ...
Breaking Medicine Technology:
(Date:2/19/2017)... ... 19, 2017 , ... Braun Industries will be participating as an exhibitor at ... take place February 23-25, 2017 at the Calvin L. Rampton Salt Palace Convention Center ... new ambulances on display. , “JEMS is a leader in EMS ...
(Date:2/19/2017)... (PRWEB) , ... February 19, 2017 , ... ... solutions for connected home healthcare, will join forces with Healthwise ® at ... education. Healthwise, the industry leader in evidence-based health education, technology and services, ...
(Date:2/18/2017)... ... February 17, 2017 , ... Butler Mobility invited Ken Matthews to visit its ... products. Ken was impressed with the safety and reliability of the Stannah Stairlift ... his show. This endorsement by Ken Matthews can be heard on News Radio ...
(Date:2/18/2017)... ... February 18, 2017 , ... ... Use Pixel Film Studios ’ ProParagraph Fashion Volume 2 for all multi-line ... other applications. Users can pick and choose from hand-crafted trend-setting designs with ...
(Date:2/17/2017)... (PRWEB) , ... February 17, 2017 , ... ... has not kept pace. Enovate Medical has introduced an innovative workstation designed to ... of supporting nurses, the Encore Mobile EHR Workstation offers a lightweight, highly mobile, ...
Breaking Medicine News(10 mins):